Individual polymorphisms in MAPT (43, 76) and GSK3B (43) have not been associated with CIPN in patients treated with taxanes or vinca alkaloids, however additive polymorphisms in MAPT and GSK3B were associated with patient and clinician reported CIPN in 454 ovarian cancer patients treated with paclitaxel and carboplatin (43). This evidence concerns the gene MAPT and ovarian carcinoma.